WO2002077176A3 - Aberrantly expressed proteins in laser capture microdissected tumors - Google Patents
Aberrantly expressed proteins in laser capture microdissected tumors Download PDFInfo
- Publication number
- WO2002077176A3 WO2002077176A3 PCT/US2002/008847 US0208847W WO02077176A3 WO 2002077176 A3 WO2002077176 A3 WO 2002077176A3 US 0208847 W US0208847 W US 0208847W WO 02077176 A3 WO02077176 A3 WO 02077176A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aberrantly expressed
- expressed proteins
- laser capture
- fingerprints
- capture microdissected
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002255880A AU2002255880A1 (en) | 2001-03-22 | 2002-03-22 | Aberrantly expressed proteins in laser capture microdissected tumors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27804801P | 2001-03-22 | 2001-03-22 | |
US60/278,048 | 2001-03-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002077176A2 WO2002077176A2 (en) | 2002-10-03 |
WO2002077176A3 true WO2002077176A3 (en) | 2004-04-01 |
Family
ID=23063475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/008847 WO2002077176A2 (en) | 2001-03-22 | 2002-03-22 | Aberrantly expressed proteins in laser capture microdissected tumors |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2002255880A1 (en) |
WO (1) | WO2002077176A2 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT412026B (en) * | 2002-02-07 | 2004-08-26 | Illmensee Karl Dr | METHOD FOR DIAGNOSING A CYSTIC OVARIAL CARCINOMA |
CA2524708C (en) | 2003-06-06 | 2009-10-06 | F. Hoffmann-La Roche Ag | Use of protein cellular retinoic acid-binding protein ii (crabp ii) as marker for breast cancer |
WO2005036180A1 (en) * | 2003-10-08 | 2005-04-21 | The Government Of The United States Of America As Represented By The Secretary Of Department Of Health And Human Services | Analysis methods using biomarkers concentrated with biomarkers attractant molecules |
WO2005124357A1 (en) * | 2004-06-18 | 2005-12-29 | Roche Diagnostics Gmbh | Use of protein elongation factor-1-alpha-1 as a marker for breast cancer |
JP2008503239A (en) | 2004-06-21 | 2008-02-07 | エクセリクシス, インク. | ACACs as IGF pathway modifiers and methods of use |
US20100173788A1 (en) * | 2005-06-21 | 2010-07-08 | Vermillion, Inc. | Biomarkers for breast cancer |
WO2007072219A2 (en) * | 2005-09-21 | 2007-06-28 | Aurelium Biopharma Inc. | Alpha enolase-directed diagnostics and therapeutics for cancer and chemotherapeutic drug resistance |
FR2894031A1 (en) * | 2005-11-25 | 2007-06-01 | Genome Express S A Sa | Method for detecting tumors and assessing their sensitivity to chemotherapy, by detecting or quantifying specific proteins or antibodies, also treatment using interfering RNA against these proteins |
US20090175871A1 (en) * | 2005-11-25 | 2009-07-09 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for demonstrating presence or absence of markers associated with the presence and/or the chemosensitivity of tumors |
JP5420396B2 (en) | 2006-04-28 | 2014-02-19 | シンガポール ヘルス サービシーズ ピーティーイー リミテッド | Examination of mucosal dryness |
IL177609A (en) | 2006-08-21 | 2015-11-30 | Yaron Ilan | Use of gabaculine or its analog in the manufacture of a medicament for treating hepatocellular carcinoma |
CN100479863C (en) * | 2006-09-06 | 2009-04-22 | 中国医学科学院北京协和医院 | Correlation of cofilin 1 and resistance to anticancer taxane chemotherapy medicine |
WO2009009890A1 (en) * | 2007-07-16 | 2009-01-22 | University Health Network | Ovarian cancer biomarkers |
KR101431062B1 (en) | 2012-03-08 | 2014-08-21 | (주)바이오메디앙 | Multiple biomarker set for breast cancer diagnosis, method of detecting the same, and diagnosis kit for breast cancer using antibody against the same |
EP3411711B1 (en) | 2016-02-04 | 2022-08-03 | Immune System Key Ltd. | Endoplasmic reticulum stress as a predictive tool in cancer therapy and a combination therapy for the treatment of cancer |
CN110031625A (en) * | 2019-03-31 | 2019-07-19 | 苏州市立医院 | Detection reagent and its application comprising 5 antibody of phosphoglucomutase |
-
2002
- 2002-03-22 AU AU2002255880A patent/AU2002255880A1/en not_active Abandoned
- 2002-03-22 WO PCT/US2002/008847 patent/WO2002077176A2/en not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
MOISEEVA ET AL.: "Characterisation of the promoter which regulates expression of a phosphoglucomutase-related protein, a component of the dystrophin/utrophin cytoskeleton predominantly expressed in smooth muscle", EUR. J. BIOCHEM., vol. 248, 1997, pages 634 - 643, XP000982239 * |
Also Published As
Publication number | Publication date |
---|---|
WO2002077176A2 (en) | 2002-10-03 |
AU2002255880A1 (en) | 2002-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002077176A3 (en) | Aberrantly expressed proteins in laser capture microdissected tumors | |
EP2100614A3 (en) | PDGFR-alpha antagonists for treatment of metastatic bone cancer | |
WO2003041562A3 (en) | Molecular cancer diagnosis using tumor gene expression signature | |
WO2004113571A3 (en) | Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis | |
WO2004046342A3 (en) | Novel gene targets and ligands that bind thereto for treatment and diagnosis of carcinomas | |
WO2002074156A3 (en) | Compositions and methods for the therapy and diagnosis of colon cancer | |
WO2002060317A3 (en) | Compositions and methods for the therapy and diagnosis of pancreatic cancer | |
WO2005062972A3 (en) | Treatment of cancer with novel anti-il 13 monoclonal antibodies | |
WO2001092581A8 (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer | |
WO2002092001A3 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
WO2002074237A3 (en) | Compositions and methods for the therapy and diagnosis of kidney cancer | |
WO2002012328A8 (en) | Compositions and methods for the therapy and diagnosis of colon cancer | |
AU2002251366A1 (en) | Proteins, genes and their use for diagnosis and treatment of breast cancer | |
WO2002057741A3 (en) | Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc) | |
WO2003037267A3 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
WO2002058534A3 (en) | Compositions and methods for the therapy and diagnosis of colon cancer | |
AU2001240909A1 (en) | Proteins, genes and their use for diagnosis and treatment of breast cancer | |
WO2005030266A3 (en) | Optical imaging of colorectal cancer | |
WO2001077168A3 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
WO2003013431A3 (en) | Compositions and methods for the therapy and diagnosis of breast cancer | |
WO2004051269A3 (en) | Ciz1 replication protein | |
EP1696028A3 (en) | Compositions and methods for the therapy and diagnosis of breast cancer | |
WO2002063951A3 (en) | Human disease modeling using somatic gene transfer | |
WO2002077232A3 (en) | Compositions and methods relating to breast specific genes and proteins | |
WO2002040673A3 (en) | Compositions and methods relating to lung specific genes and proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |